Preclinical safety evaluation of AAV2-sFLT01- a gene therapy for age-related macular degeneration.

[1]  Magali Saint-Geniez,et al.  An essential role for RPE-derived soluble VEGF in the maintenance of the choriocapillaris , 2009, Proceedings of the National Academy of Sciences.

[2]  A. J. Roman,et al.  Human RPE65 gene therapy for Leber congenital amaurosis: persistence of early visual improvements and safety at 1 year. , 2009, Human gene therapy.

[3]  G. Veres,et al.  An efficient rHSV-based complementation system for the production of multiple rAAV vector serotypes , 2009, Gene Therapy.

[4]  Magali Saint-Geniez,et al.  Endogenous VEGF Is Required for Visual Function: Evidence for a Survival Role on Müller Cells and Photoreceptors , 2008, PloS one.

[5]  W. Hauswirth,et al.  Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. , 2008, Human gene therapy.

[6]  Kathleen A. Marshall,et al.  Safety and efficacy of gene transfer for Leber's congenital amaurosis. , 2008, The New England journal of medicine.

[7]  Nick Tyler,et al.  Effect of gene therapy on visual function in Leber's congenital amaurosis. , 2008, The New England journal of medicine.

[8]  P. Campochiaro,et al.  Prolonged blockade of VEGF family members does not cause identifiable damage to retinal neurons or vessels , 2008, Journal of cellular physiology.

[9]  R. Bakay,et al.  Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2–neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial , 2008, The Lancet Neurology.

[10]  T. Flotte,et al.  Clinical gene therapy using recombinant adeno-associated virus vectors , 2008, Gene Therapy.

[11]  Olivier Hermine,et al.  Phenotypic and Genotypic Characteristics of Mastocytosis According to the Age of Onset , 2008, PloS one.

[12]  David Eidelberg,et al.  Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial , 2007, The Lancet.

[13]  Susan Schneider,et al.  Ranibizumab versus verteporfin for neovascular age-related macular degeneration. , 2006, The New England journal of medicine.

[14]  Philip J Rosenfeld,et al.  Ranibizumab for neovascular age-related macular degeneration. , 2006, The New England journal of medicine.

[15]  D. Guyer,et al.  Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. , 2006, Ophthalmology.

[16]  P. Campochiaro,et al.  Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a phase I clinical trial. , 2006, Human gene therapy.

[17]  Peter Carmeliet,et al.  Angiogenesis in life, disease and medicine , 2005, Nature.

[18]  W. Hauswirth,et al.  Long-term restoration of rod and cone vision by single dose rAAV-mediated gene transfer to the retina in a canine model of childhood blindness. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[19]  I. Constable,et al.  Long-term evaluation of AAV-mediated sFlt-1 gene therapy for ocular neovascularization in mice and monkeys. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[20]  Ivana K. Kim,et al.  Safety and efficacy of intravitreal injection of ranibizumab in combination with verteporfin PDT on experimental choroidal neovascularization in the monkey. , 2005, Archives of ophthalmology.

[21]  Alan McClelland,et al.  Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector , 2000, Nature Genetics.

[22]  R. Nussenblatt,et al.  Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. , 1985, Ophthalmology.

[23]  W. Hauswirth,et al.  Novel anti-VEGF chimeric molecules delivered by AAV vectors for inhibition of retinal neovascularization , 2009, Gene Therapy.

[24]  M. Agbandje-McKenna,et al.  The Role of the Adeno-Associated Virus Capsid in Gene Transfer , 2008, Methods in molecular biology.

[25]  M. Abrahamowicz,et al.  Health and Quality of Life Outcomes , 2006 .

[26]  A. Suburo,et al.  Development of the endothelium. , 2006, Handbook of experimental pharmacology.